APNT Nanoparticle Formulation Platform

 

Model: APNT

Category: Pharmaceutical

Exhibitor: FORMOSA PHARMACEUTICALS , INC

Booth No: M318

 

Characteristic

 

√ APNT® is Formosa Pharma’s proprietary formulation platform developed to enhance the dissolution and bioavailability of poorly soluble drugs by reducing particle size to the nanoscale.
√ Unlike traditional milling methods, APNT® technology does not use metal or plastic beads, thereby eliminating the risk of contamination from bead debris.
√ Instead, it employs high-purity salts and sugars as milling media, which are safe and can be integrated into the final formulation.
√ The APNT® platform is highly versatile, suitable for oral dosage forms, dry powder inhalers (DPIs), nebulized respiratory therapies, topical dermatological treatments, and ophthalmic drug delivery.
√ The platform’s druggability has been validated by the U.S. FDA approval in 2024 and Health Canada Approval of APP13007 in 2026 —a novel ophathalmic drug derived from APNT® technology.
√ APNT® nanoparticle formulations have also been demonstrated to work effectively with mesh-type nebulizers, allowing for efficient inhalation delivery.

 

Other Products

 

• 

  TSY-110 - Kadcyla (T-DM1) Biosimilar

• 

  APP13007 - Clobetasol Propionate Ophthalmic Suspension 0.05% for the treatment of post-operative inflammation and pain following ocular surgery

• 

  TSY-120 - Enhertu (T-DXd) Biosimilar

• 

  TSY-310 - A Next-Generation Novel Bispecific ADC

• 

  APP13002 - Infectious Eye Diseases Treatment

 

 

 

Back